Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma, University of Arkansas for Medical Sciences Study
10/17/2007 9:37:04 AM
LITTLE ROCK, Ark.--(BUSINESS WIRE)--Skin cancer specialists at the University of Arkansas for Medical Sciences’ (UAMS) Winthrop P. Rockefeller Cancer Institute (formerly the Arkansas Cancer Research Center) are recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. If Allovectin-7® is found to be safe and effective in clinical trials, it may offer patients a new option for fighting advanced melanoma (stage 3 or stage 4). Safety and efficacy data from a Phase 2 clinical trial of Allovectin-7® were presented at the 2006 American Society of Clinical Oncology (ASCO) meeting. The ongoing Phase 3 study is designed to determine whether more patients with advanced melanoma respond favorably to Allovectin-7® alone than to current standard chemotherapy alone. To find out whether you or someone you know qualifies for the study, please visit www.melanomatrial.com.